Pharmacokinetic-pharmacodynamic modeling of diltiazem in spontaneously hypertensive rats: A microdialysis study

Journal of Pharmacological and Toxicological Methods

Volumn 56, Issue 3, 2007, Pages 290-299

  Bertera, Facundo M ^a   Mayer, Marcos A ^a   Opezzo, Javier A W ^a   Taira, Carlos A ^a   Bramuglia, Guillermo F ^a   Höcht, Christian ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Chronotropic effect; Diltiazem; Hypotensive effect; Microdialysis; Pharmacokinetic pharmacodynamic modeling; Plasma pharmacokinetics; Spontaneously hypertensive rats

Indexed keywords

DILTIAZEM;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CAROTID ARTERY; CHRONOTROPISM; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG SENSITIVITY; HEART RATE; HYPERTENSION; MALE; MEAN ARTERIAL PRESSURE; MICRODIALYSIS; NONHUMAN; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; WISTAR KYOTO RAT;

ALGORITHMS; ANIMALS; ANTIHYPERTENSIVE AGENTS; AREA UNDER CURVE; BLOOD PRESSURE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIALYSIS SOLUTIONS; DILTIAZEM; DOSE-RESPONSE RELATIONSHIP, DRUG; HEART RATE; INJECTIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; MICRODIALYSIS; MODELS, BIOLOGICAL; RATS; RATS, INBRED SHR; RATS, INBRED WKY; SPECIES SPECIFICITY;

ANIMALIA; RATTUS;

EID: 35148875606     PISSN: 10568719     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vascn.2007.04.001     Document Type: Article

References (43)

1. Bloedow D.C., Piepho R.W., Nies A.S., and Gal J. Serum binding of diltiazem in humans. Journal of Clinical Pharmacology 22 (1982) 201-205
2. Brynne L., Karlsson M.O., and Paalzow L.K. Concentration-effect relationship of l-propranolol and metoprolol in spontaneous hypertensive rats after exercise-induced tachycardia. Journal of Pharmacology and Experimental Therapeutics 286 (1998) 1152-1158
3. Chiappe de Cingolani G.E. Adipocyte responsiveness to norepinephrine in spontaneoulsy hypertensive rats. Metabolism 37 (1988) 318-322
4. Csajka C., and Verotta D. Pharmacokinetic-pharmacodynamic modeling: History and perspectives. Journal of Pharmacokinetics and Pharmacodynamics 33 (2006) 227-279
5. Downing S.J., Edwards D., and Hollingsworth M. Diltiazem pharmacokinetics in the rat and relationship between its serum concentration and uterine and cardiovascular effects. British Journal of Pharmacology 91 (1987) 735-745
6. Echizen H., and Eichelbaum M. Clinical pharmacokinetics of verapamil, nifedipine and diltiazem. Clinical Pharmacokinetics 11 (1986) 425-449
7. Eisner G.M., Asico L.D., Albrecht F.E., and Jose P.A. Dopamine and diltiazem-induced natriuresis in the spontaneously hypertensive rat. American Journal of Physiology 273 (1997) R317-R323
8. Elliot L.A., and Jamali F. Pharmacokinetics and pharmacodynamics of nifedipine in untreated and atorvastatin-treated hyperlipidemic rats. The Journal of Pharmacology and Experimental Therapeutics 291 (1999) 188-193
9. Flaim S.F., and Zelis R.F. Regional distribution of cardiac output in conscious rats at rest and during exercise. Effects of diltiazem. Chest 78 (1980) 187-192
10. Frohlich E.D. Calcium antagonists. Their physiological differences. American Journal of Hypertension 4 (1991) 430S-433S
11. Gibaldi M., and Perrier D. Pharmacokinetics. 2nd ed. (1982), Marcel Dekker Inc., New York
12. Hajri T., Ibrahimi A., Coburn C.T., Knapp F.F., Kurtz T., Praveneci M., et al. Defective fatty acid uptake in the spontaneously hypertensive rat is a primary determinant of altered glucose metabolism, hyperinsulinemia, and myocardial hypertrophy. Journal Biological Chemistry 276 (2001) 23661-23666
13. Harder S., Thurmann P., and Rietbrock N. Concentration/effect analysis of antihypertensive drugs. American Journal of Therapeutics 1 (1994) 116-124
14. Herrera A.M., Scott D.O., and Lunte C.E. Microdialysis sampling for determination of plasma protein binding of drugs. Pharmaceutical Research 7 (1990) 1077-1081
15. Höcht C., Di Verniero C., Opezzo J.A.W., Bramuglia G.F., and Taira C.A. Pharmacokinetic-pharmacodynamic (PK-PD) modeling of cardiovascular effects of metoprolol in spontaneously hypertensive rats: A microdialysis study. Naunyn-Schmiedeberg's Archives of Pharmacology 373 (2006) 310-318
16. Höcht C., Di Verniero C., Opezzo J.A.W., and Taira C.A. Pharmacokinetic-pharmacodynamic properties of metoprolol in chronic aortic coarctated rats. Naunyn-Schmiedeberg's Archives of Pharmacology 370 (2004) 1-8
17. Höcht C., Di Verniero C., Opezzo J.A.W., and Taira C.A. Application of the microdialysis technique for the pharmacokinetic-pharmacodynamic (PK-PD) modeling of beta-blockers. Journal of Pharmacological and Toxicological Methods 52 (2005) 244-250
18. Höcht C., Opezzo J.A.W., Bramuglia G.F., and Taira C.A. Application of microdialysis for pharmacokinetic-pharmacodynamic modelling. Expert Opinion on Drug Discovery 1 (2006) 289-301
19. Höcht C., Opezzo J.A.W., and Taira C.A. Validation of a new intraarterial microdialysis shunt probe for the estimation of pharmacokinetic parameters. Journal of Pharmaceutical and Biomedical Analysis 31 (2003) 1105-1113
20. Höcht C., Opezzo J.A.W., and Taira C.A. Microdialysis in drug discovery. Current Drug Discovery Technologies 1 (2004) 269-285
21. Hoffman B.B. Therapy of hypertension. In: Brunton L.L., Lazo J.S., and Parker K.L. (Eds). Goodman and Gilman's the Pharmacological Basis of Therapeutics. 11 edition (2006), Mc Graw Hill, New York 845-868
22. Isanta J.R., Lasheras B., Fos D., and Cenarruzabeitia E. Comparative diltiazem plasma clearance in normotensive and hypertensive rats. Journal of Pharmaceutical Sciences 76 (1987) 862-865
23. Isanta J.R., Lasheras B., Fos D., and Cenarruzabeitia E. Kinetics of pharmacological effect of diltiazem in spontaneous hypertensive rats. Methods and Findings in Experimental and Clinical Pharmacology 9 (1987) 661-667
24. Joo E.H., and Lee Y.B. No effect of diltiazem on the hepatic clearance of indocyanine green in the rats. Archives of Pharmacal Research 21 (1998) 411-417
25. Kitareewan S., and Walz Jr. F.G. Genetic and developmental diversity of hepatic cytochromes P450. Warfarin and progesterone metabolism by hepatic microsomes from four inbred strains of rat. Drug Disposition and Metabolism 22 (1994) 607-615
26. Le Quellec A., Dupin S., Tufenkji A.E., Genissel P., and Houin G. Microdialysis: An alternative for in vitro and in vivo protein binding studies. Pharmaceutical Research 11 (1994) 835-838
27. Loch J.M., Potter J., and Bachmann K.A. The influence of anesthetic agents on rat hepatic cytochromes P450 in vivo. Pharmacology 50 (1995) 146-153
28. McAllister Jr. R.G., Schloemer G.L., and Hamann S.R. Kinetics and dynamics of calcium entry antagonists in systemic hypertension. American Journal of Cardiology 57 (1986) 16D-21D
29. Meneguz A., Fortuna S., Lorenzini P., and Volpe M.T. Influence of urethane and ketamine on rat hepatic cytochrome P450 in vivo. Experimental and Toxicological Pathology 51 (1999) 392-396
30. Meredith P.A. Clinical relevance of optimal pharmacokinetics in the treatment of hypertension. Journal of Hypertension 15 suppl 5 (1997) S27-S31
31. Meredith P.A., and Elliot H.L. Concentration-effect relationships and implications for trough-to-peak ratio. American Journal of Hypertension 9 (1996) 66S-70S
32. Naritomi Y., Terashita S., Kagayama A., and Sugiyama Y. Utility of hepatocytes in predicting drug metabolism: Comparison of hepatic intrinsic clearance in rats and humans in vivo and in vitro. Drug Metabolism and Disposition 31 (2003) 580-588
33. Nelson K.M., Sheperd R.E., and Spitzer J.A. Lipolysis and betaadrenergic receptor binding on adipocytes of spontaneously hypertensive rats. Biochemical Medicine and Metabolic Biology 37 (1987) 51-60
34. Opezzo J.A.W., Höcht C., Taira C.A., and Bramuglia G.F. Pharmacokinetic study of methyldopa in aorta-coarctated rats using a microdialysis technique. Pharmacological Research 43 (2001) 155-159
35. Piepho R.W., Bloedow D.C., Lacz J.P., Runser D.J., Dimmit D.C., and Browne R.K. Pharmacokinetics of diltiazem in selected animal species and human beings. American Journal of Cardiology 49 (1982) 525-528
36. Reid J.L., and Meredith P.A. Concentration-effect analysis of antihypertensive drug responses. Hypertension 16 (1990) 12-18
37. Schoemaker R.C., van Gerven J.M.A., and Cohen A.F. Estimating potency for the Emax-model without attaining maximal effects. Journal of Pharmacokinetics and Biopharmaceutics 26 (1998) 581-593
38. Schramm L., Heidbreder E., Lukes M., Weierich T., Lopau K., Zimmermann J., et al. Endotoxin-induced acute renal failure in the rat: Effects of urodilatin and diltiazem on renal function. Clinical Nephrology 46 (1996) 117-124
39. Spitzer J.A., Burns A.H., and O'Malley P.J. Catecholamine-stimulated lipolysis in adipocytes of spontaneously hypertensive rats. Biochemical Medicine 34 (1985) 100-106
40. Ståhle L. Pharmacokinetic estimations from microdialysis data. European Journal of Clinical Pharmacology 43 (1992) 289-294
41. Toutain P.L. Pharmacokinetic/pharmacodynamic integration in drug development and dosage-regimen optimization for veterinary medicine. AAPS Pharmaceutical Sciences 4 (2002) 1-29
42. Tsui B.C., Feng J.D., and Yeung P.K. Pharmacokinetics and haemodynamic effect of diltiazem in rats: Effect of route of administration. Journal of Pharmacy and Pharmacology 50 (1998) 183-188
43. Yeung P.K., Feng J.D., and Buckley S.J. Pharmacokinetics and hypotensive effect of diltiazem in rabbits: Comparison of diltiazem with its major metabolites. Journal of Pharmacy and Pharmacology 50 (1998) 1247-1253